+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Infectious Enteritis Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 276 Pages
  • May 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 5991234
The global market for Infectious Enteritis Treatment was estimated at US$387.6 Million in 2025 and is projected to reach US$590.7 Million by 2032, growing at a CAGR of 6.2% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Infectious Enteritis Treatment Market - Key Trends and Drivers Summarized

Infectious enteritis is an inflammation of the intestines caused by a variety of pathogens, including bacteria, viruses, and parasites. Common culprits include rotavirus, norovirus, Escherichia coli, and Salmonella, which can lead to symptoms such as diarrhea, abdominal pain, vomiting, and fever. The disease transmission typically occurs through consumption of contaminated food or water, or direct contact with infected individuals. Treatment for infectious enteritis depends on the severity of the symptoms and the specific pathogen involved. For viral infections, management is generally supportive, focusing on hydration and electrolyte balance, as antibiotics are not effective. For bacterial or parasitic infections, specific antimicrobials are prescribed based on the organism identified through stool tests or other diagnostic methods. In all cases, maintaining hydration is critical, especially for vulnerable populations such as young children and the elderly, who are at higher risk of severe dehydration.

The approach to managing infectious enteritis has evolved with advances in diagnostic tools and treatment strategies. Rapid diagnostic tests have become increasingly available, enabling quicker identification of the causative agent and appropriate management to be initiated sooner. This is particularly important in preventing the spread of infections in community settings and during outbreaks. Furthermore, there has been significant progress in developing and disseminating guidelines for the treatment and prevention of enteritis, including recommendations for the use of vaccines where available, such as those against rotavirus. Public health initiatives focusing on improving water quality, promoting hand hygiene, and educating about safe food handling practices also play a crucial role in reducing the incidence of infectious enteritis globally.

The growth in the infectious enteritis treatment market is driven by several factors, including global population growth, increased awareness of the disease, and advancements in medical treatments and diagnostic technologies. As the global population increases, particularly in developing regions, there is a higher burden of enteric infections due to challenges in sanitation, clean water access, and public health infrastructure. This drives demand for both preventive measures and effective treatments. Advancements in genomic and molecular diagnostic techniques allow for more rapid and accurate pathogen identification, which in turn supports the development of targeted therapies. Additionally, the rising awareness of the importance of disease prevention through vaccines and public health education contributes to market growth. Consumer behavior has shifted towards seeking quicker, more effective treatments, including rehydration solutions and probiotics, which are gaining popularity for their perceived benefits in supporting gut health. These dynamics indicate a robust ongoing demand for innovative and effective solutions in the treatment of infectious enteritis.

Report Scope

The report analyzes the Infectious Enteritis Treatment market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Drug Type (Antibiotics, Antiviral Drugs, Other Drug Types); Route of Administration (Oral Administration, Injectables Administration).
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Antibiotics segment, which is expected to reach US$335.2 Million by 2032 with a CAGR of 6.9%. The Antiviral Drugs segment is also set to grow at 5.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $119.9 Million in 2025, and China, forecasted to grow at an impressive 9.9% CAGR to reach $143.0 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Infectious Enteritis Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Infectious Enteritis Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Infectious Enteritis Treatment Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AdvaCare Pharma, Astellas Pharma, Inc., Caspian Tamin Pharmaceutical Co., Centurion Healthcare Private Limited, Merck & Co., Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Infectious Enteritis Treatment market report include:

  • AdvaCare Pharma
  • Astellas Pharma, Inc.
  • Caspian Tamin Pharmaceutical Co.
  • Centurion Healthcare Private Limited
  • Merck & Co., Inc.
  • Tokushukai Medical Group

Domain Expert Insights

This market report incorporates insights from domain experts across enterprise, industry, academia, and government sectors. These insights are consolidated from multilingual multimedia sources, including text, voice, and image-based content, to provide comprehensive market intelligence and strategic perspectives. As part of this research study, the publisher tracks and analyzes insights from 43 domain experts. Clients may request access to the network of experts monitored for this report, along with the online expert insights tracker.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind
  • Global Economic Update
  • Infectious Enteritis Treatment - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Global Incidences of Infectious Enteritis Drive Urgency for Effective Treatment Solutions
  • Advances in Microbiome Research Strengthen Business Case for Targeted Enteritis Therapies
  • Growth in Travel and Exposure to Novel Pathogens Sets the Stage for Broader Enteritis Treatment Needs
  • Development of Rapid Diagnostic Tests for Enteric Pathogens Enhances Treatment Efficiency
  • Growing Focus on Pediatric and Elderly Populations Drives Specialized Treatment Approaches
  • Consumer Preferences for Alternative and Herbal Medicines Impact Traditional Treatment Markets
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Infectious Enteritis Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Infectious Enteritis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Infectious Enteritis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Antiviral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Antiviral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Antiviral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Injectables Administration by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Injectables Administration by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Injectables Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Infectious Enteritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 21: USA Historic Review for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 22: USA 13-Year Perspective for Infectious Enteritis Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics, Antiviral Drugs and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 23: USA Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 24: USA Historic Review for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 25: USA 13-Year Perspective for Infectious Enteritis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2020, 2026 & 2032
CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 27: Canada Historic Review for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 28: Canada 13-Year Perspective for Infectious Enteritis Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics, Antiviral Drugs and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 29: Canada Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 30: Canada Historic Review for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 31: Canada 13-Year Perspective for Infectious Enteritis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2020, 2026 & 2032
JAPAN
  • Infectious Enteritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
  • Table 32: Japan Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 33: Japan Historic Review for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 34: Japan 13-Year Perspective for Infectious Enteritis Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics, Antiviral Drugs and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 35: Japan Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 36: Japan Historic Review for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 37: Japan 13-Year Perspective for Infectious Enteritis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2020, 2026 & 2032
CHINA
  • Infectious Enteritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
  • Table 38: China Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 39: China Historic Review for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 40: China 13-Year Perspective for Infectious Enteritis Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics, Antiviral Drugs and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 41: China Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 42: China Historic Review for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 43: China 13-Year Perspective for Infectious Enteritis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2020, 2026 & 2032
EUROPE
  • Infectious Enteritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
  • Table 44: Europe Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • Table 45: Europe Historic Review for Infectious Enteritis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 46: Europe 13-Year Perspective for Infectious Enteritis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
  • Table 47: Europe Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 48: Europe Historic Review for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 49: Europe 13-Year Perspective for Infectious Enteritis Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics, Antiviral Drugs and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 50: Europe Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 51: Europe Historic Review for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 52: Europe 13-Year Perspective for Infectious Enteritis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2020, 2026 & 2032
FRANCE
  • Infectious Enteritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
  • Table 53: France Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 54: France Historic Review for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 55: France 13-Year Perspective for Infectious Enteritis Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics, Antiviral Drugs and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 56: France Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 57: France Historic Review for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 58: France 13-Year Perspective for Infectious Enteritis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2020, 2026 & 2032
GERMANY
  • Infectious Enteritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
  • Table 59: Germany Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 60: Germany Historic Review for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 61: Germany 13-Year Perspective for Infectious Enteritis Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics, Antiviral Drugs and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 62: Germany Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 63: Germany Historic Review for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 64: Germany 13-Year Perspective for Infectious Enteritis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2020, 2026 & 2032
ITALY
  • Table 65: Italy Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 66: Italy Historic Review for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 67: Italy 13-Year Perspective for Infectious Enteritis Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics, Antiviral Drugs and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 68: Italy Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 69: Italy Historic Review for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 70: Italy 13-Year Perspective for Infectious Enteritis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2020, 2026 & 2032
UNITED KINGDOM
  • Infectious Enteritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
  • Table 71: UK Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 72: UK Historic Review for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 73: UK 13-Year Perspective for Infectious Enteritis Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics, Antiviral Drugs and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 74: UK Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 75: UK Historic Review for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 76: UK 13-Year Perspective for Infectious Enteritis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2020, 2026 & 2032
SPAIN
  • Table 77: Spain Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 78: Spain Historic Review for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 79: Spain 13-Year Perspective for Infectious Enteritis Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics, Antiviral Drugs and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 80: Spain Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 81: Spain Historic Review for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 82: Spain 13-Year Perspective for Infectious Enteritis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2020, 2026 & 2032
RUSSIA
  • Table 83: Russia Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 84: Russia Historic Review for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 85: Russia 13-Year Perspective for Infectious Enteritis Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics, Antiviral Drugs and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 86: Russia Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 87: Russia Historic Review for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 88: Russia 13-Year Perspective for Infectious Enteritis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2020, 2026 & 2032
REST OF EUROPE
  • Table 89: Rest of Europe Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 90: Rest of Europe Historic Review for Infectious Enteritis Treatment by Drug Type - Antibiotics, Antiviral Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 91: Rest of Europe 13-Year Perspective for Infectious Enteritis Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics, Antiviral Drugs and Other Drug Types for the Years 2020, 2026 & 2032
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • Table 93: Rest of Europe Historic Review for Infectious Enteritis Treatment by Route Of Administration - Oral Administration and Injectables Administration Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • Table 94: Rest of Europe 13-Year Perspective for Infectious Enteritis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectables Administration for the Years 2020, 2026 & 2032
AUSTRALIA
  • Infectious Enteritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
INDIA
  • Infectious Enteritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
SOUTH KOREA
REST OF ASIA-PACIFIC
LATIN AMERICA
  • Infectious Enteritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINA
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
  • Infectious Enteritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRAN
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
  • Infectious Enteritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AdvaCare Pharma
  • Astellas Pharma, Inc.
  • Caspian Tamin Pharmaceutical Co.
  • Centurion Healthcare Private Limited
  • Merck & Co., Inc.
  • Tokushukai Medical Group

Table Information